26 May 2020 - Rockwell Medical today announced the filing of a new drug submission with Health Canada for Triferic AVNU (ferric pyrophosphate citrate).
The Company seeks an indication to promote Triferic AVNU in Canada for the replacement of iron to maintain haemoglobin in adult patients with haemodialysis dependent chronic kidney disease.
The filing is the first international regulatory submission for the intravenous therapy.